Article

Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients.

The Journal of Clinical Psychiatry (Impact Factor: 5.14). 02/2005; 66(1):135-6. DOI: 10.4088/JCP.v66n0118c
Source: PubMed
1 Follower
 · 
40 Views
 · 
0 Downloads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of cases are reported in which patients on aripiprazole have developed akathisia, although the literature states that the rate is negligible.
    Neuropsychiatric Disease and Treatment 07/2006; 2(2):241-3. DOI:10.2147/nedt.2006.2.2.241 · 2.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aripiprazole, a novel atypical antipsychotic that acts as a partial agonist at the dopamine D(2) receptors, has been reported to be effective in the treatment of chronic schizophrenia. However, the risks and benefits of using aripiprazole in the acute hospital setting to treat severe psychotic disorders are unclear. This naturalistic study assessed the effectiveness of aripiprazole monotherapy in a group of actively psychotic male patients (n = 10) with schizophrenia who were admitted to an inner-city acute psychiatric unit. Most patients (n = 7) responded to aripiprazole treatment, which was well tolerated and significantly ameliorated psychotic symptoms after 2-3 weeks. Patients who responded to it could be safely discharged on aripiprazole monotherapy. Side effects observed were mostly mild and transient, and included extrapyramidal symptoms (n = 1) and neutropenia (n = 1). Aripiprazole also remarkably attenuated dyskinetic movements in 1 patient with severe tardive dyskinesia, thereby suggesting that it may be useful in the treatment of other disorders that are also associated with dopamine dysfunction. Results showed that aripiprazole can be safely and effectively employed in the hospital setting to treat severely psychotic patients with schizophrenia, but further studies are required to establish the full range of adverse reactions and therapeutic indications associated with its use.
    Neuropsychiatric Disease and Treatment 07/2006; 2(2):191-7. DOI:10.2147/nedt.2006.2.2.191 · 2.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is a case report of a 56-year-old lady who was admitted to a psychiatric ward because she was showing a plethora of positive and negative symptoms of schizophrenia. She has a positive history of mental illness; her mother had a diagnosis of schizophrenia. The patient did not have any medical history of relevance and was not taking any medication. She was commenced on Aripiprazole and after 5 weeks developed disabling extra-pyramidal side effects. On discontinuation of Aripiprazole, the side effects subsided and disappeared quickly. According to the authors' knowledge, this is the first case of a patient developing extra-pyramidal side effects following treatment with Aripiprazole, not previously exposed to other antipsychotic, and with no co-morbid medical conditions. The authors suggest titrating Aripiprazole slowly.
    Journal of Psychopharmacology 08/2006; 20(4):592-3. DOI:10.1177/0269881106060194 · 2.81 Impact Factor
Show more